TC BioPharm Isn't at Risk of Delisting, Company Says

Dow Jones10-26

By Josh Beckerman

TC BioPharm criticized a "false social media claim" about a potential delisting and added that "there is absolutely no way the company is in any danger of being delisted" from Nasdaq.

The biotechnology company said it remains in compliance with all Nasdaq listing requirements. It said it will look to take action to defend itself from attacks intended to creative negative market dynamics.

The Motherwell, Scotland, company's American depositary receipts fell 55% on Monday. ADRs were higher Tuesday and closed lower in each of the next two sessions, and were recently down 16%, to $1.67, Friday.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

October 25, 2024 13:41 ET (17:41 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2478954449?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-26 01:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2478954449","market":"fut","top_or_hot":-1,"title":"TC BioPharm Isn't at Risk of Delisting, Company Says","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/TCBP\">TC BioPharm</a> criticized a \"false social media claim\" about a potential delisting and added that \"there is absolutely no way the company is in any danger of being delisted\" from Nasdaq. \n</p>\n<p>\n  The biotechnology company said it remains in compliance with all Nasdaq listing requirements. It said it will look to take action to defend itself from attacks intended to creative negative market dynamics. \n</p>\n<p>\n  The Motherwell, Scotland, company's American depositary receipts fell 55% on Monday. ADRs were higher Tuesday and closed lower in each of the next two sessions, and were recently down 16%, to $1.67, Friday. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 25, 2024 13:41 ET (17:41 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TC BioPharm Isn't at Risk of Delisting, Company Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTC BioPharm Isn't at Risk of Delisting, Company Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-26 01:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Josh Beckerman \n\n\n \n\n\nTC BioPharm criticized a \"false social media claim\" about a potential delisting and added that \"there is absolutely no way the company is in any danger of being delisted\" from...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4009","symbol_name":"广告","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2478954449","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2478954449","pubTimestamp":1729878060,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"TC BioPharm criticized a \"false social media claim\" about a potential delisting and added that \"there is absolutely no way the company is in any danger of being delisted\" from Nasdaq.The biotechnology company said it remains in compliance with all Nasdaq listing requirements. It said it will look to take action to defend itself from attacks intended to creative negative market dynamics.The Motherwell, Scotland, company's American depositary receipts fell 55% on Monday. ADRs were higher Tuesday and closed lower in each of the next two sessions, and were recently down 16%, to $1.67, Friday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4009":"广告","TC":"团车","TCBP":"TC BioPharm","BK4139":"生物科技"},"translate_title":"TC BioPharm表示不存在退市风险","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TC":1,"TCBP":1,"NQmain":0.77},"content_text":"By Josh Beckerman \n\n\n \n\n\nTC BioPharm criticized a \"false social media claim\" about a potential delisting and added that \"there is absolutely no way the company is in any danger of being delisted\" from Nasdaq. \n\n\n  The biotechnology company said it remains in compliance with all Nasdaq listing requirements. It said it will look to take action to defend itself from attacks intended to creative negative market dynamics. \n\n\n  The Motherwell, Scotland, company's American depositary receipts fell 55% on Monday. ADRs were higher Tuesday and closed lower in each of the next two sessions, and were recently down 16%, to $1.67, Friday. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 25, 2024 13:41 ET (17:41 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2478954449"}